SIC
IBRX icon

SJS Investment Consulting’s ImmunityBio IBRX Stock Holding History

SJS Investment Consulting’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03K Buy
118
+108
+1,080% +$817 ﹤0.01% 2022
2026
Q1 		$77 Sell
10
-54
-84% -$370 ﹤0.01% 2180
2025
Q4 		$127 Buy
+64
New +$145 ﹤0.01% 1914
2025
Q2 		– Sell
-9
Closed -$28 – 1598
2025
Q1 		$28 Sell
9
-41
-82% -$124 ﹤0.01% 1583
2024
Q4 		$128 Buy
50
+32
+178% +$133 ﹤0.01% 1503
2024
Q3 		$67 Sell
18
-40
-69% -$185 ﹤0.01% 1599
2024
Q2 		$367 Buy
58
+47
+427% +$310 ﹤0.01% 1387
2024
Q1 		$60 Buy
+11
New +$50 ﹤0.01% 1601
2023
Q2 		– Sell
-3
Closed -$6 – 1611
2023
Q1 		$6 Sell
3
-1
-25% -$3 ﹤0.01% 1576
2022
Q4 		$20 Buy
+4
New +$22 ﹤0.01% 1580
2022
Q1 		$0 Buy
+1
New +$6 ﹤0.01% 1000

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SJS Investment Consulting's IBRX Position: Q2 2026 in Review

SJS Investment Consulting increased its ImmunityBio (IBRX) stake by 1,080% in Q2 2026, buying an estimated $817 and bringing the position to 118 shares worth $1.03K. The position accounts for ﹤0.01% of the portfolio, ranked #2022.

SJS Investment Consulting first reported a position in IBRX in Q1 2022 and has held it in 11 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • SJS Investment Consulting held 118 shares of ImmunityBio worth $1.03K as of Q2 2026.
  • SJS Investment Consulting bought 108 ImmunityBio shares in Q2 2026, an estimated $817.
  • ImmunityBio made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2022 holding.
  • SJS Investment Consulting first reported a position in ImmunityBio in Q1 2022 and has held it in 11 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.